Cancer-associated thoracic aorta arterial thrombosis: case report and review of the literature.

IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Frontiers in Cardiovascular Medicine Pub Date : 2025-01-29 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1480310
Miguel Borregón, María Valero, Asia Ferrández, Álvaro Muñoz, Carmen Roque, Javier-David Benítez-Fuentes
{"title":"Cancer-associated thoracic aorta arterial thrombosis: case report and review of the literature.","authors":"Miguel Borregón, María Valero, Asia Ferrández, Álvaro Muñoz, Carmen Roque, Javier-David Benítez-Fuentes","doi":"10.3389/fcvm.2025.1480310","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge.</p><p><strong>Key clinical question: </strong>Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed.</p><p><strong>Clinical approach: </strong>We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy.</p><p><strong>Conclusions: </strong>This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1480310"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1480310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge.

Key clinical question: Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed.

Clinical approach: We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy.

Conclusions: This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症相关胸主动脉血栓:病例报告及文献回顾。
背景:动脉血栓形成是癌症患者中一种罕见的并发症,通常被静脉血栓栓塞事件所掩盖。它的发生在积极的抗肿瘤治疗的实体肿瘤患者提出了重大的临床挑战。关键临床问题:鉴于对癌症患者动脉血栓形成的最佳治疗方法缺乏共识,必须回顾处理主动脉血栓的最佳实践和低分子肝素(LMWH)的益处。临床方法:我们报告一位70岁女性IVA期肺腺癌患者在化疗免疫治疗期间发生主动脉血栓。低分子肝素成功地治疗了血栓,避免了进一步的并发症,并允许她继续癌症治疗。结论:本病例强调了早期发现和处理癌症患者动脉血栓的重要性。低分子肝素被证明在解决血栓方面是有效的,强调了其在处理此类并发症中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.80
自引率
11.10%
发文量
3529
审稿时长
14 weeks
期刊介绍: Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
期刊最新文献
Cardiac surgery in an infant hemophilia B carrier with moderate hemophilia: a case report. Case Report: A case of giant left ventricular aneurysm resulting in LAD compression and stenosis. Cardiovascular complications in chronic active Epstein-Barr virus infection: a narrative review. Global burden and trend of ischemic heart disease and its attributable risk factors among women of childbearing age from 1990 to 2021. Prevalence and characterization of heart failure in Aragon, Spain (ICAR study).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1